Biogen’s stock hit by soft guidance and a decline in sales of MS drugs

1 month ago 10
ARTICLE AD BOX
Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset below-consensus EPS outlook.
Read Entire Article
  1. Homepage
  2. Finance
  3. Biogen’s stock hit by soft guidance and a decline in sales of MS drugs

Related

Under Trump, AI Scientists Are Told to Remove ‘Ideological Bias’ From Powerful Models

Under Trump, AI Scientists Are Told to Remove ‘Ideological B...

9 hours ago 2
Fintech Klarna files for IPO at a weak point for public debuts

Fintech Klarna files for IPO at a weak point for public debu...

11 hours ago 2
This Wall Street pro saw the stock-market chaos coming. He says investors should wait to buy again.

This Wall Street pro saw the stock-market chaos coming. He s...

11 hours ago 3

Trending

1. waff 48
2. wfie weather
3. terrifier 3
4. ellen degeneres
5. carabao cup
6. ios 18.3.2
7. stake us
8. wombats australia
9. weather evansville
10. severe thunderstorm watch

Popular

Netflix scuttles plans to add six previously announced games to its service

Netflix scuttles plans to add six previously announced games...

1 month ago 124
Steam will label early access games that haven't been updated in a year

Steam will label early access games that haven't been update...

1 month ago 90
OpenAI co-founder John Schulman has left Anthropic after less than a year

OpenAI co-founder John Schulman has left Anthropic after les...

1 month ago 85
Google's Magic Editor will watermark its AI-tweaked photos

Google's Magic Editor will watermark its AI-tweaked photos

1 month ago 82
Metal Gear Solid Delta: Snake Eater release date leaks on the PlayStation Store

Metal Gear Solid Delta: Snake Eater release date leaks on th...

1 month ago 79
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Nexa News 2025. All rights are reserved